Counselors in San Joaquin, CA Accepting Medicare
2 Counselors found. Showing 1 - 2
 Guadalupe Maldonado, LCSW Counselor - Mental Health Medicare: Medicare Enrolled Practice Location: 21890 W Colorado Ave, San Joaquin, CA 93660 Phone: 559-693-2462 |
Maria Torres Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 22305 California Ave, San Joaquin, CA 93660 Phone: 559-367-6950 |
News Archive
Minnetronix introduces new Cognita remote medical device monitoring and intelligence system
Minnetronix, a provider of award-winning product design, development and manufacturing services to the medical device and life science marketplaces, is pleased to announce the introduction of its latest product offering: the Minnetronix® Cognita™ System. The system will be debuted at the Medical Design & Manufacturing West Expo on February 8-10, in Anaheim, California.
FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS
EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its proprietary metformin-based product candidate, EX404, for the treatment of pediatric polycystic ovary syndrome (PCOS).
Low blood phosphorus levels associated with high death rates in African AIDS patients: Research
Low blood phosphorus levels are associated with high death rates in the initial weeks of antiretroviral therapy (ART) in AIDS patients in sub-Saharan Africa, according to new research conducted by University of Alabama at Birmingham researchers at the UAB-affiliated Centre for Infectious Disease Research in Zambia.
Diabetes in Control announces clinical slide presentation library for medical community
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
FDA stops pain drug trial over safety concerns
Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.
› Verified 9 days ago